MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Down 57.0% in September

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) was the target of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 255,600 shares, a decrease of 57.0% from the August 31st total of 593,900 shares. Based on an average daily volume of 5,550,000 shares, the short-interest ratio is currently 0.0 days. Approximately 2.6% of the company’s shares are sold short.

Institutional Trading of MIRA Pharmaceuticals

Large investors have recently bought and sold shares of the business. Cross Staff Investments Inc bought a new stake in shares of MIRA Pharmaceuticals during the 1st quarter valued at about $422,000. Virtu Financial LLC lifted its stake in MIRA Pharmaceuticals by 330.2% in the first quarter. Virtu Financial LLC now owns 63,055 shares of the company’s stock valued at $69,000 after buying an additional 48,397 shares during the period. Suncoast Equity Management bought a new position in shares of MIRA Pharmaceuticals during the 1st quarter worth approximately $44,000. Finally, Praetorian Wealth Management Inc. acquired a new stake in shares of MIRA Pharmaceuticals during the 1st quarter worth approximately $30,000. 35.16% of the stock is currently owned by institutional investors and hedge funds.

MIRA Pharmaceuticals Trading Down 2.7 %

MIRA stock traded down $0.03 during trading on Thursday, hitting $1.07. The company had a trading volume of 186,158 shares, compared to its average volume of 2,217,859. The stock has a market cap of $15.81 million and a PE ratio of -1.64. The business has a 50-day moving average of $1.86 and a 200-day moving average of $1.21. MIRA Pharmaceuticals has a one year low of $0.51 and a one year high of $6.40.

MIRA Pharmaceuticals (NASDAQ:MIRA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Research analysts forecast that MIRA Pharmaceuticals will post -0.6 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets initiated coverage on MIRA Pharmaceuticals in a report on Monday, August 5th. They set a “buy” rating and a $11.00 target price on the stock.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.